Abstract
The Centers for Disease Control and Prevention’s (CDC) Well-Integrated Screening and Evaluation for WOMen Across the Nation (WISEWOMAN) program funded 24 recipients to provide cardiovascular disease screenings and healthy behavior support services to uninsured and underinsured women aged 40–64 years. In 2018 and throughout the COVID-19 pandemic, WISEWOMAN recipients implemented evidence-based strategies to reduce participants’ risk for cardiovascular disease, including team-based care through medication therapy management (MTM) and self-measured blood pressure (SMBP) monitoring, as well as other clinical and health behavior support services. Our primary analysis assessed the implementation of MTM and SMBP and changes in implementation. To contextualize implementation, we analyzed participants’ engagement in MTM and SMBP. We analyzed data from 108 semi-structured interviews with WISEWOMAN staff and partners, program survey responses from 22 of 24 funded recipients, and participant-level data from 5,541 participants. Interview respondents noted the value of MTM and SMBP, especially during the COVID-19 pandemic, while also describing challenges arising from implementing strategies (e.g., integrating MTM into clinic workflows, time and resources needed for SMBP). In 2023, 71% of recipients reported referring participants to MTM, compared to 41% of recipients in 2020. The percentage of hypertensive participants who reported monitoring their blood pressure at least weekly increased from 36% at the first screening to 44% at the second screening (p < .01). Health systems seeking to implement team-based care for hypertension management and control can draw upon experiences from 24 recipients who have successfully implemented MTM and SMBP to address cardiovascular disease.
Keywords
Get full access to this article
View all access options for this article.
